Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yiyang Wang
Observed name:
Y Wang
Institution:
First Affiliated Hospital of Xinjiang Medical University
Observed institutions:
University of Pittsburgh,
Shanghai Jiao Tong University,
Renji Hospital,
First Affiliated Hospital of Xinjiang Medical University,
Eureka Therapeutics (United States),
UPMC Hillman Cancer Center,
University of Pittsburgh Medical Center,
Tsinghua University
show all 8
ORCID:
0000-0001-6207-4716
Observed ORCID:
0000-0001-6207-4716
OpenAlex ID:
A5081283753
IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell
2019
·
Lulu Shao
, Weizhou Hou
, et al.
·
Cancer Immunology Research
·
90
Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior T cells for cancer immunotherapy
2025
·
Andrew T. Frisch
, Yiyang Wang
, et al.
·
Cell Metabolism
·
56
PDF
Metastasis-associated phosphatase PRL-2 regulates tumor cell migration and invasion
2011
·
Y Wang
, J S Lazo
·
Oncogene
·
50
Integrated Pan-Cancer Profiling and Breast Cancer Validation Identify BEND3 as a Potential Prognostic and Immune Biomarker
2025
·
Yuting Gou
, Yongxiang Li
, et al.
·
Breast Cancer Targets and Therapy
·
26
The value of Protein Phosphatase Methylesterase 1 in diagnosis, prognosis and immunoregulation: from pan-cancer analysis to breast cancer verification
2026
·
Yiyang Wang
, Yue Zhang
, et al.
·
Frontiers in Immunology
·
24
PDF
Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) in adults with moderately to severely active systemic lupus erythematosus: a phase I dose-escalation study
2025
·
Yiyang Wang
, Shaoying Yang
, et al.
·
Journal of Autoimmunity
·
11
Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date
2019
·
PD Zavras
, Y Wang
, et al.
·
OncoTargets and Therapy
·
9
PDF
A Bi-Specific T Cell Engaging Monoclonal Antibody (mAb) Derived From a TCR-Like Mab Specific For WT1/HLA-A0201 (ESK-BiTE) Shows a Potent Activity Against Human AML and Ph+ ALL In Mouse Models
2013
·
Dmitry Pankov
, Tao Dao
, et al.
·
Blood
·
5
Pan-cancer analysis and breast cancer validation reveal DEAD-box helicase 23 as a crucial prognostic and immuno-biomarker
2026
·
Haotian Ma
, Xiyidan Aimaiti
, et al.
·
Scientific Reports
·
4
Data from IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell
2023
·
Lulu Shao
, Weizhou Hou
, et al.
Figure S4 from IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell
2023
·
Lulu Shao
, Weizhou Hou
, et al.
Figure S3 from IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell
2023
·
Lulu Shao
, Weizhou Hou
, et al.
PDF
Figure S3 from IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell
2023
·
Lulu Shao
, Weizhou Hou
, et al.
Figure S2 from IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell
2023
·
Lulu Shao
, Weizhou Hou
, et al.
Figure S1 from IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell
2023
·
Lulu Shao
, Weizhou Hou
, et al.
PDF
Figure S1 from IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell
2023
·
Lulu Shao
, Weizhou Hou
, et al.
Data from IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell
2023
·
Lulu Shao
, Weizhou Hou
, et al.
Supplementary Figure legends from IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell
2023
·
Lulu Shao
, Weizhou Hou
, et al.
PDF
Figure S4 from IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell
2023
·
Lulu Shao
, Weizhou Hou
, et al.
PDF
Figure S2 from IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell
2023
·
Lulu Shao
, Weizhou Hou
, et al.
PDF
Show more works
View as search
Works count:
20
Citation count:
283
H-index:
7
I10-index:
6
Year
Topic
Type